Dr. Shin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1365 Clifton Rd NE
Atlanta, GA 30322Phone+1 404-778-1900Fax+1 404-778-5520
Summary
- I am a professor of medical oncology focusing on the patient care and research in head and neck cancer and thyroid cancer.
And I am also a translational physician scientist focusing on drug discovery with nanotechnology and cancer prevention with natural compounds, and biomarker studies. I have had peer reviewed funding over the decades for such research and published more than 390 research articles.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1982 - 1985
Yonsei University College of MedicineClass of 1975
Certifications & Licensure
CA State Medical License 2012 - 2026
GA State Medical License 2003 - 2025
PA State Medical License 2001 - 2004
TX State Medical License 1987 - 2003
IL State Medical License 1983 - 1987- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Member of EUAS European Union of Academy of Science, 2018
- FAAAS American Association of Advancement of Science, 2016
- KBS Global Award in Science and Technology Korea Broadcasting System (KBS), 2015
- Join now to see all
Clinical Trials
- Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 2003 Nov 26
- Erlotinib Prevention of Oral Cancer (EPOC) Start of enrollment: 2006 Nov 03
- Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck Start of enrollment: 2010 Mar 01
Publications & Presentations
PubMed
- 114 citationsNanotechnology for targeted cancer therapyMay D. Wang, Dong M. Shin, Jonathan W. Simons, Shuming Nie
Expert Review of Anticancer Therapy. 2007-06-01 - 56 citationsHPV Positive Squamous Cell Carcinoma of the Oropharynx. Are we Observing an Unusual Pattern of MetastasesSusan Muller, Fadlo R. Khuri, Scott A. Kono, Jonathan J. Beitler, Dong M. Shin
Head and Neck Pathology. 2012-04-15 - 123 citationsHFT-T, a Targeting Nanoparticle, Enhances Specific Delivery of Paclitaxel to Folate Receptor-Positive TumorsXu Wang, Jun Li, Yiqing Wang, Kwang Jae Cho, Gloria J. Kim
ACS Nano. 2009-10-27
Journal Articles
- Concurrent Chemoradiotherapy with Weekly Versus Triweekly Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Comparative AnalysisRathi Pillai, Fadlo R Khuri, Nabil F Saba, Conor Steuer, Suchita Pakkala, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Brandon Twardy, Kelly Schrapp, Taof..., Head & Neck
- Interleukin-6/STAT3 Signaling Is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell CarcinomaNabil F Saba, Dong M Shin, Head and Neck Pathology
- Article MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK ActivationGuojing Zhang, Fadlo R Khuri, Taofeek K Owonikoko, Dan Li, Conor E Steuer, Nabil F Saba, Dong M Shin, Sagar Lonial, ScienceDirect
Press Mentions
Research Roundup: Recent Grants and Publications for Emory Faculty and StaffMay 22nd, 2023- Shop TalkFebruary 10th, 2015
New Drug Combination Could Prevent Head and Neck Cancer in High-Risk PatientsFebruary 19th, 2013- Join now to see all
Grant Support
- Tumor membrane vesicle (TMV) vaccine immunotherapy in head and neck cancerNIH2023–2028
- Toxicity And Efficacy Of GOLD Nanoparticle Photothermal Therapy In CancerNational Cancer Institute2010–2011
- Spore In Head And Neck CancerNational Cancer Institute2007–2011
- Second Primary Tumor Prevention W/Egfr Tkis, COX-2 Inhibitors Head &Neck CancerNational Cancer Institute2007–2011
- Chemoprevention With Green TEA Polyphenon E (PPE) And Egfr-Tkis In Head And NeckNational Cancer Institute2007–2011
- Nanotherapeutics: Multifunctional Nanoparticles For Drug Delivery And TargetingNational Cancer Institute2008–2009
- Chemoprevention Of Head And Neck Cancer With ZD1839 And CelecoxibNational Cancer Institute2007–2008
- Administration CoreNational Cancer Institute2007
- Second Primary Tumor Prevention W/Egfr Tkis &Cox-2 Inhibitors In H &N CancerNational Cancer Institute2006
- Chemoprevention Of The Head And Neck Cancer With Zd1839*National Cancer Institute2005–2006
- Core--Clinical Support/BiostatisticsNational Institute Of Dental &Craniofacial Research2002–2006
- Chemoprevention Of Head And Neck CancerNational Cancer Institute2004
- Randomized Adjuvant Therapy Of Head And Neck CancerNational Cancer Institute2000–2001
- Randomized Adjuvant Therapy Of Head And Neck CancerNational Cancer Institute1998–1999
- Adjuvant Biologic Therapy For Stage III/IV Head CancerNational Cancer Institute1997–1998
Professional Memberships
- Member
Other Languages
- Korean
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
